Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by intro..
Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) and Incyte Corporation (Nasdaq: INCY) have announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial successfully met its primary endpoint, demonstrating an overall response rate (ORR) of 74% when administered at a dose of 0.3 mg/kg every two weeks. Furthermore, the data reve..
Vir Biotechnology has released the topline data from its Phase 2 PENINSULA trial, which evaluated VIR-2482 for the prevention of seasonal influenza A illness. According to the announcement made on July 20, 2023, VIR BIOTECHNOLOGY Inc. reported that the trial did not meet its primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), there was a..
Hoth Therapeutics, a biopharmaceutical company focused on patient care, has recently received protocol approval for its cancer therapeutic, HT-001. This exciting development was announced on July 19, 2023.   The FDA-approved trial now has two sites approved for conducting the study, and additional sites are currently in the approval process. This means that recruitment of patients can now be..
The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment.   In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..
